These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23796729)

  • 41. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
    Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
    BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
    Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK; Minshall ME; Shen W; Xie S; Silverman SL
    J Rheumatol; 2003 Jul; 30(7):1579-83. PubMed ID: 12858462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of teriparatide adherence and persistence on fracture outcomes.
    Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
    Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
    Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
    Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Middle East experience from the Asia And Latin America Fracture Observational Study (ALAFOS): Baseline characteristics of postmenopausal women with osteoporosis using teriparatide.
    Elsalmawy AA; Al-Ali NS; Yaghi Y; Assaggaf H; Maalouf G; Sadat-Ali M; Zaher E; Saghieh S; Mahmoud A; Taher M
    J Int Med Res; 2020 Aug; 48(8):300060520940855. PubMed ID: 32762404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
    Krege JH; Wan X
    Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.
    Ohta H; Hamaya E; Taketsuna M; Sowa H
    Curr Med Res Opin; 2015 Jan; 31(1):85-94. PubMed ID: 25299349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
    Lindsay R; Miller P; Pohl G; Glass EV; Chen P; Krege JH
    Osteoporos Int; 2009 Jun; 20(6):943-8. PubMed ID: 18923884
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider.
    Kyvernitakis I; Kostev K; Kurth A; Albert US; Hadji P
    Osteoporos Int; 2014 Dec; 25(12):2721-8. PubMed ID: 25011986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis.
    Yuan F; Peng W; Yang C; Zheng J
    Int J Surg; 2019 Jun; 66():1-11. PubMed ID: 30890377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
    Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
    Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
    Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
    J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
    Oswald AJ; Berg J; Milne G; Ralston SH
    Calcif Tissue Int; 2014 Feb; 94(2):176-82. PubMed ID: 24026567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conducting an observational study during an economic crisis: analysis of the treatment and follow-up phase of Greek patients participating in the ExFOS study.
    Aloumanis K; Kapetanos G; Alexandridis T; Drossinos V; Papaioannou N;
    Hormones (Athens); 2018 Dec; 17(4):531-540. PubMed ID: 30430458
    [TBL] [Abstract][Full Text] [Related]  

  • 58. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS).
    Sato M; Tsujimoto M; Kajimoto K; Uetake H; Shimoda H; Fujiwara S
    Arch Osteoporos; 2018 Jul; 13(1):74. PubMed ID: 29978364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case report: Teriparatide treatment in a case of severe pregnancy -and lactation- associated osteoporosis.
    Lampropoulou-Adamidou K; Trovas G; Stathopoulos IP; Papaioannou NA
    Hormones (Athens); 2012; 11(4):495-500. PubMed ID: 23422774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.